Comparison of Efonidipine/Irbesartan combination and Irbesartan monotherapy for uncontrolled hypertension

Comparison of Efonidipine/Irbesartan combination and Irbesartan monotherapy for uncontrolled hypertension - Efonidipine and Irbesartan Therapy for Hypertension in Kyoto

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002242

Enrollment

100

Registered

2009-09-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

200mg Irbesartan od 100mg irbesartan + 40mg efonidipine od

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: uncontrolled hypertensive patients treated with anti-hypertensive drugs based on the guideline released from Japanese Society of Hypertension in 2009

Exclusion criteria

Exclusion criteria: 1. pregnant patients 2. patients with severe liver dysfunction 3. patients with severe renal dysfunction 4. allergic to irbesartan or efonidipine 5. patients judged to be inappropriate for this study by attending physicians

Design outcomes

Primary

Measure	Time frame
blood pressure lowering after 1 month	—

Secondary

Measure	Time frame
1. blood pressure lowering after 6 months 2. Change in albuminuria after 6 months 3. adverse events	—

Countries

Japan

Contacts

Public ContactHidenori Arai

Kyoto University Graduate School of Medicine Department of Human Health Sciences

harai@kuhp.kyoto-u.ac.jp075-751-3861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026